Title: Microbiota-derived short-chain fatty acids do not interfere with SARS-CoV-2 infection of human colonic samples
Author: Falvella, Ana Caroline Brambilla; Martins de souza, Daniel; Smith, Bradley J.; Silva'costa, Licia C.; Valenca, A. G.; Crunfli, F.; Zuardi, A. W.; Hallak, J. E.; Crippa, J. A.; De Almeida, Valéria
Is part of: Frontiers in Molecular Neuroscience, v. 14, p. 673144 -
Citation: Falvella, Ana Caroline Brambilla; Martins de souza, Daniel; Smith, Bradley J.; Silva'costa, Licia C.; Valenca, A. G.; Crunfli, F.; Zuardi, A. W.; Hallak, J. E.; Crippa, J. A.; De Almeida, Valéria; Microbiota-derived short-chain fatty acids do not interfere with SARS-CoV-2 infection of human colonic samples. Frontiers in Molecular Neuroscience, v.14, p. 673144-, 2021
Abstract: The 14-3-3 family comprises multifunctional proteins that play a role in neurogenesis, neuronal migration, neuronal differentiation, synaptogenesis and dopamine synthesis. 14-3-3 members function as adaptor proteins and impact a wide variety of cellular and physiological processes involved in the pathophysiology of neurological disorders. Schizophrenia is a psychiatric disorder and knowledge about its pathophysiology is still limited. 14-3-3 have been proven to be linked with the dopaminergic, glutamatergic and neurodevelopmental hypotheses of schizophrenia. Further, research using genetic models has demonstrated the role played by 14-3-3 proteins in neurodevelopment and neuronal circuits, however a more integrative and comprehensive approach is needed for a better understanding of their role in schizophrenia. For instance, we still lack an integrated assessment of the processes affected by 14-3-3 proteins in the dopaminergic and glutamatergic systems. In this context, it is also paramount to understand their involvement in the biology of brain cells other than neurons. Here, we present previous and recent research that has led to our current understanding of the roles 14-3-3 proteins play in brain development and schizophrenia, perform an assessment of their functional protein association network and discuss the use of protein-protein interaction modulators to target 14-3-3 as a potential therapeutic strategy.
Funding: This work was supported by the CAPES (465412/2014-9) and S~ao Paulo Research Foundation (2016/07332-7, 2017/255881, 2019/22398-2).